ZA200809115B - Use of antisecretory factors for treating intraocular hypertension - Google Patents

Use of antisecretory factors for treating intraocular hypertension

Info

Publication number
ZA200809115B
ZA200809115B ZA200809115A ZA200809115A ZA200809115B ZA 200809115 B ZA200809115 B ZA 200809115B ZA 200809115 A ZA200809115 A ZA 200809115A ZA 200809115 A ZA200809115 A ZA 200809115A ZA 200809115 B ZA200809115 B ZA 200809115B
Authority
ZA
South Africa
Prior art keywords
intraocular hypertension
antisecretory factors
treating intraocular
treating
antisecretory
Prior art date
Application number
ZA200809115A
Other languages
English (en)
Inventor
Hansson Hans-Arne
Stefan Lange
Jennische Eva
Original Assignee
Lantmaennen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab
Publication of ZA200809115B publication Critical patent/ZA200809115B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA200809115A 2006-04-27 2008-10-23 Use of antisecretory factors for treating intraocular hypertension ZA200809115B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600932 2006-04-27

Publications (1)

Publication Number Publication Date
ZA200809115B true ZA200809115B (en) 2009-07-29

Family

ID=38561776

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809115A ZA200809115B (en) 2006-04-27 2008-10-23 Use of antisecretory factors for treating intraocular hypertension

Country Status (18)

Country Link
US (2) US8207296B2 (https=)
EP (2) EP2015767B1 (https=)
JP (2) JP5284948B2 (https=)
KR (1) KR20090040404A (https=)
CN (2) CN102633863B (https=)
AU (1) AU2007244004B2 (https=)
BR (1) BRPI0710959B8 (https=)
CA (2) CA2771087C (https=)
DK (2) DK2468292T3 (https=)
ES (2) ES2561945T3 (https=)
IL (1) IL194773A (https=)
MX (1) MX2008013769A (https=)
NZ (2) NZ598426A (https=)
PL (2) PL2015767T3 (https=)
RU (1) RU2458703C2 (https=)
SG (1) SG171602A1 (https=)
WO (1) WO2007126364A2 (https=)
ZA (1) ZA200809115B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013769A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Uso de factores antisecretores para el tratamiento de hipertension intraocular.
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
WO2010093324A1 (en) * 2009-02-11 2010-08-19 Lantmännen As-Faktor Ab Use of antisecretory factors (af) for optimizing cellular uptake
WO2013050795A1 (en) * 2011-10-03 2013-04-11 Femtonics Kft. Use of photoactive compounds
EP2934564B1 (en) * 2012-12-20 2018-05-23 Lantmännen AS-Faktor AB Antisecretory factor (af) for use in the treatment of glioblastoma
US11253552B2 (en) 2015-07-10 2022-02-22 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of AF-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
JP7217760B2 (ja) 2018-06-28 2023-02-03 ラントメネン・メディカル・アーベー 急性呼吸不全の治療および／または予防の使用のための抗分泌因子
CN112770643A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
EP3855935A1 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted wheat
AU2021243735A1 (en) 2020-03-26 2022-10-13 Lantmännen Functional Foods Ab A consumable product comprising malted cereals for promoting recovery at physical activity
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
SE9604251L (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
CA2340721A1 (en) * 1999-06-21 2001-01-25 George Tuszynski Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
RU2192898C1 (ru) * 2001-08-16 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
MX2008013769A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Uso de factores antisecretores para el tratamiento de hipertension intraocular.
MX2008013777A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
KR101757523B1 (ko) * 2006-04-27 2017-07-12 란트만넨 아스-팍토르 아베 구획 증후군의 치료에 사용하기 위한 항분비 단백질

Also Published As

Publication number Publication date
RU2008146733A (ru) 2010-06-10
EP2468292A1 (en) 2012-06-27
AU2007244004A1 (en) 2007-11-08
PL2015767T3 (pl) 2016-05-31
US20120283191A1 (en) 2012-11-08
RU2458703C2 (ru) 2012-08-20
US8207296B2 (en) 2012-06-26
IL194773A (en) 2015-07-30
EP2468292B8 (en) 2020-02-26
CN102633863B (zh) 2014-08-06
EP2015767B1 (en) 2016-01-06
MX2008013769A (es) 2009-02-03
PL2468292T3 (pl) 2020-08-24
BRPI0710959B1 (pt) 2018-11-06
DK2468292T3 (da) 2020-03-23
KR20090040404A (ko) 2009-04-24
WO2007126364A2 (en) 2007-11-08
ES2561945T3 (es) 2016-03-01
US9000125B2 (en) 2015-04-07
JP2012153695A (ja) 2012-08-16
BRPI0710959A2 (pt) 2012-02-28
DK2015767T3 (en) 2016-02-08
CN102633863A (zh) 2012-08-15
BRPI0710959B8 (pt) 2021-05-25
CA2650344A1 (en) 2007-11-08
WO2007126364A3 (en) 2008-03-06
IL194773A0 (en) 2011-08-01
JP5284948B2 (ja) 2013-09-11
CN101432013B (zh) 2015-01-07
AU2007244004B2 (en) 2012-02-09
JP2009535329A (ja) 2009-10-01
WO2007126364A8 (en) 2009-07-23
NZ598426A (en) 2012-08-31
US20090162296A1 (en) 2009-06-25
CA2650344C (en) 2017-10-31
CN101432013A (zh) 2009-05-13
NZ572255A (en) 2012-03-30
ES2773945T3 (es) 2020-07-15
EP2468292B1 (en) 2019-12-18
CA2771087A1 (en) 2007-11-08
EP2015767A2 (en) 2009-01-21
SG171602A1 (en) 2011-06-29
CA2771087C (en) 2016-03-15

Similar Documents

Publication Publication Date Title
ZA200809115B (en) Use of antisecretory factors for treating intraocular hypertension
EP2051725A4 (en) METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS
IL193451A0 (en) Surgical devices for treating pelvic conditions
ZA200810105B (en) Means for controlling the progression of myopia
SI2306977T1 (sl) Postopek in sestavek za zdravljenje oäśesne hipertenzije in glavkoma
EP1993539A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
ZA200700663B (en) Process for dewatering ethanol
PL2101777T3 (pl) Kompozycja do leczenia nadciśnienia płucnego
PL2010717T3 (pl) Sposób obudowy ścian wykopów
GB2446944B (en) Removal of prosthesis
EP2161334A4 (en) METHOD FOR DETERMINING THE RISK OF PROGRESSION OF GLAUCOMA
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
IL198005A0 (en) Ccr2 antagonists for treatment of fibrosis
ZA200807713B (en) Thiazolyldihydrocyclopentapyrazoles for use as PI3-kinase inhibitors
IL198941A0 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
EP1940397A4 (en) METHOD FOR TREATING HYPERTONIA
EP1993536A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1993537A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1996191A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
EP2003971A4 (en) RNAI-mediated inhibition of status in association with the histamine receptor H1
ZA200807615B (en) Renin inhibitors for the treatment of hypertension
SG121993A1 (en) Process for influencing the properties of combustion residue
EP1993538A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
GB0820885D0 (en) A composition for the treatment of hypertension
EP2056811A4 (en) MODAFINIL TREATMENT AGAINST EARLY EJACULATION